Early Life and Education
Timothy Springer was born in Fort Benning, Georgia, in 1948. His father was a physician. Springer attended public high school in California and enrolled at the University of California, Berkeley, where he majored in biochemistry, graduating with a B.A. in 1971. He pursued his Ph.D. under Jack Strominger at Harvard University, completing it in 1976 with a dissertation on membrane-embedded major histocompatibility glycoproteins. During the Vietnam War, Springer volunteered as a VISTA community development volunteer on the Yomba Shoshone Reservation in Nevada.
Rise to Success
Springer's career took off when he joined the Harvard Medical School faculty in 1977. He became an associate professor in 1983 and was appointed Latham Family Professor in 1989. Springer's research focused on the immune system, discovering lymphocyte function-associated molecules, which led to the development of several FDA-approved antibody-based therapies. Springer founded LeukoSite in 1993, which went public in 1997 and was acquired by Millennium Pharmaceuticals in 1999. Springer's early investments in companies like Moderna, where he invested $5 million in 2010, proved highly lucrative, contributing significantly to his wealth. His investment in Moderna resulted in a 17,000% return. Eli Lilly's $3.2 billion acquisition of Morphic Holding, a biotech firm Springer founded in 2014, is set to bring him a nine-digit windfall.
Key Business Strategies
Springer has utilized a strategy of identifying promising scientific research and investing in or founding companies to commercialize it. He focuses on biotechnology and has a knack for recognizing the potential of new technologies like mRNA. His early investment in Moderna, which developed a COVID-19 vaccine, exemplifies this strategy. He also co-founded and invested in multiple other biotech companies, including Scholar Rock, Morphic Therapeutic, Tectonic Therapeutic, and Seismic Therapeutic.
Philanthropy
Beyond his business success, Springer is also known for his philanthropic efforts. In 2017, he co-founded the Institute for Protein Innovation (IPI), a nonprofit organization focused on protein science and research. Springer has donated a total of $250 million to the institute.